The Biotech Investment Paradigm
Latest Post
Will the FDA Remove Zevalin's Bioscan?
In the next few days, the FDA is expected to announce whether or not Spectrum Pharmaceuticals’ (NASDAQ: SPPI) Zevalin should still require a pre-treatment screen, termed the “bioscan”, possibly removing what management believes is the last hurdle to a dramatic increase in Zevalin prescriptions. Zevalin is an antibody attached to Yttrium-90, a radioactive isotope that [...]
Featured Posts
In the next few days, the FDA is expected to announce whether or not Spectrum Pharmaceuticals’ (NASDAQ: SPPI) Zevalin should still require a pre-treatment screen, termed the “bioscan”, possibly removing what management believes is the last hurdle to a dramatic increase in Zevalin prescriptions. Zevalin is an antibody attached to Yttrium-90, a radioactive isotope that [...]
© 2012 The Biotech Investment Paradigm. All Rights Reserved.
Powered by WordPress. Designed by 
Recent Comments